Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

Business Management

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastrointestinal Cancer

Urothelial Cancer

Prostate Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Non-Hodgkin Lymphoma

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

Matthew Pierre Deek, MD, discusses the significance of pretreatment immune cell infiltration in patients with muscle-invasive bladder cancer who had been treated with definitive chemoradiation.

Dr Deek on the Investigation of Immune Cell Infiltration in MIBC

Patients with breast cancer who received hypofractionated postmastectomy radiotherapy experienced similar toxicities vs those who received conventionally fractionated postmastectomy radiotherapy, according to a presentation shared at the 2023 American Society for Radiation Oncology Annual Meeting. 

Hypofractionated and Conventionally Fractionated Radiotherapy Generate Similar QOL, Safety in Breast Cancer

Bradford (Brad) S. Hoppe, MD, MPH, discusses the rationale for investigating consolidative radiotherapy in place of autologous stem cell transplant in patients with low-risk, relapsed/refractory classic Hodgkin lymphoma who have been previously treated with nivolumab plus brentuximab vedotin, as investigated in the phase 2 CheckMate 744 study, as well as key findings from this trial.


Dr Hoppe on the Rationale for the CheckMate 744 Trial in Hodgkin Lymphoma

Michael Chuong, MD, FACRO, discusses patterns of locoregional recurrence following guided radiation therapy in pancreatic cancer.


Dr Chuong on the Patterns of Guided Radiation Therapy in Pancreatic Cancer

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements And Featured Publications

All Publications

CME/CE

Resources

Biomarker Consortium

Interactive Tools

Learning Modules

Presentations

Subscribe

Print Subscription

eNewsletter

joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

, and now serves as the main digital news writer for 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Takeda to Voluntarily Withdraw Mobocertinib for EGFR Exon 20 Insertion+ NSCLC

The FDA has granted de novo marketing authorization for the Invitae Common Hereditary Cancers Panel, an in vitro diagnostic test designed to detect genetic variants associated with an elevated risk of developing certain types of cancer.

FDA Grants Marketing Authorization to First DNA Test to Assess Genetic Predisposition to Select Cancers

A new drug application seeking the approval of fruquintinib for the treatment of adult patients with previously treated metastatic colorectal cancer has been submitted to Japan’s Ministry of Health, Labour, and Welfare.

Japanese Approval Sought for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Share your views with OncChats 

Specialty

Authors

Eirwen M. Miller, MD, discusses the current treatment landscape of ovarian cancer.


Dr. Miller on the Current Treatment Landscape of Ovarian Cancer

Eirwen M. Miller, MD, discusses the safety and efficacy of veliparib vs other PARP inhibitors used in the treatment of patients with ovarian cancer.

Dr. Miller on the Safety, Efficacy of Veliparib Vs Other PARP Inhibitors in Ovarian Cancer

Eirwen M. Miller, MD, discusses the potential utility of sequential PARP inhibition in ovarian cancer.  



Dr. Miller on the Potential Utility of Sequential PARP Inhibition in Ovarian Cancer 

Eirwen M. Miller, MD, discusses her approach to frontline maintenance therapy in ovarian cancer.  



Dr. Miller on Approaching Frontline Maintenance Therapy in Ovarian Cancer 

Eirwen M. Miller, MD

Articles

Latest Conference Coverage